SPC News Staff
The FDA approved nadofaragene firadenovec-vncg (Adstiladrin, Ferring Pharmaceuticals), the first gene therapy for adults with high-risk bacillus Calmette-Guérin (BCG)-unresponsive non–muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.
Nadofaragene firadenovec-vncg is a nonreplicating adenoviral vector–based gene therapy containing the gene interferon alfa-2b, administered by catheter into the bladder once every